Abstract:Abstract Background The situation faced by breast cancer patients, especially those with triple-negative breast cancer, is still grave. More effective therapeutic targets are needed to optimize the clinical management of breast cancer. Although collagen type VIII alpha 1 chain (COL8A1) has been shown to be downregulated in BRIP1-knockdown breast cancer cells, its clinical role in breast cancer remains unknown. Methods Gene microarrays and mRNA sequencing data were downloaded and integrated into larger matrices based on various platforms. Therefore, this is a multi-centered study, which contains 5048 breast cancer patients and 1161 controls. COL8A1 mRNA expression in breast cancer was compared between molecular subtypes. In-house immunohistochemistry staining was used to evaluate the protein expression of COL8A1 in breast cancer. A diagnostic test was performed to assess its clinical value. Furthermore, based on differentially expressed genes (DEGs) and co-expressed genes (CEGs) positively related to COL8A1, functional enrichment analyses were performed to explore the biological function and potential molecular mechanisms of COL8A1 underlying breast cancer. Results COL8A1 expression was higher in breast cancer patients than in control samples (standardized mean difference = 0.79; 95% confidence interval [CI] 0.55–1.03). Elevated expression was detected in various molecular subtypes of breast cancer. An area under a summary receiver operating characteristic curve of 0.80 (95% CI 0.76–0.83) with sensitivity of 0.77 (95% CI 0.69–0.83) and specificity of 0.70 (95% CI 0.61–0.78) showed moderate capacity of COL8A1 in distinguishing breast cancer patients from control samples. Worse overall survival was found in the higher than in the lower COL8A1 expression groups. Intersected DEGs and CEGs positively related to COL8A1 were significantly clustered in the proteoglycans in cancer and ECM-receptor interaction pathways. Conclusions Elevated COL8A1 may promote the migration of breast cancer by mediating the ECM-receptor interaction and synergistically interplaying with DEGs and its positively related CEGs independently of molecular subtypes. Several genes clustered in the proteoglycans in cancer pathway are potential targets for developing effective agents for triple-negative breast cancer.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the clinical value of collagen VIII α1 chain (COL8A1) in breast cancer and its underlying mechanisms. Specifically, the researchers hope: 1. **Evaluate the expression level of COL8A1 in different molecular subtypes of breast cancer**: By analyzing gene microarray and mRNA sequencing data sets, compare the expression differences of COL8A1 between breast cancer patients and the control group, and explore its expression in different molecular subtypes (such as Luminal A, Luminal B, HER - 2+ and triple - negative breast cancer). 2. **Verify the protein expression level of COL8A1**: Through immunohistochemical staining methods, further confirm the protein expression level of COL8A1 in breast cancer tissues. 3. **Evaluate the diagnostic and prognostic value of COL8A1**: By drawing the receiver operating characteristic curve (ROC) and calculating the area under the curve (AUC), evaluate the ability of COL8A1 to distinguish breast cancer patients from healthy control groups; at the same time, through survival analysis, explore the relationship between the expression level of COL8A1 and the prognosis of breast cancer patients. 4. **Explore the molecular mechanism of COL8A1 in breast cancer**: By identifying co - expressed genes (CEGs) and differentially expressed genes (DEGs) with COL8A1, and performing functional enrichment analysis, to reveal the potential biological functions and molecular mechanisms of COL8A1 in the occurrence and development of breast cancer. In summary, this study aims to comprehensively analyze the role of COL8A1 in breast cancer, provide a theoretical basis for future clinical applications, and lay the foundation for further understanding the pathogenesis of breast cancer and finding effective treatment targets.

Clinical value and potential mechanisms of COL8A1 upregulation in breast cancer: a comprehensive analysis